United Therapeutics (UTHR) Goodwill & Intangibles (2010 - 2026)
United Therapeutics (UTHR) reported Goodwill & Intangibles of $115.5 million for Q1 2026, up 3.4% on a YoY basis from $111.7 million in Q1 2025, and down 0.86% sequentially from $116.5 million in Q4 2025.
United Therapeutics (UTHR) Goodwill & Intangibles (2010 - 2026) Analysis & Trends
United Therapeutics (UTHR) has 17 years of Goodwill & Intangibles data on file, last reported at $115.5 million in Q1 2026.
- For the quarter ending Q1 2026, Goodwill & Intangibles rose 3.4% year-over-year to $115.5 million; the trailing twelve-month figure through Mar 2026 stood at $115.5 million (up 3.4% YoY), and the FY2025 full-year result was $116.5 million, up 4.11% from the prior year.
- Goodwill & Intangibles retreated to $115.5 million in Q1 2026, from $116.5 million in the prior quarter.
- In the past five years, Goodwill & Intangibles ranged from a high of $116.7 million in Q3 2025 to a low of $44.4 million in Q3 2023.
- A 5-year average of $85.4 million and a median of $111.7 million in 2025 frame the typical range for Goodwill & Intangibles.
- Across the five-year window, Goodwill & Intangibles surged 159.33% in 2024 and dropped 3.21% in 2025, its largest moves.
- Tracing UTHR's Goodwill & Intangibles over 5 years: stood at $44.5 million in 2022, then soared by 156.63% to $114.2 million in 2023, then retreated by 2.01% to $111.9 million in 2024, then grew by 4.11% to $116.5 million in 2025, then fell by 0.86% to $115.5 million in 2026.
- Business Quant data shows UTHR's Goodwill & Intangibles at $115.5 million in Q1 2026, $116.5 million in Q4 2025, and $116.7 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 89.28 Bn | 87.42 Bn | - |
| 2 | Teva Pharmaceutical Industries | 35.85 Bn | 32.11 Bn | 1.97 Bn |
| 3 | Zoetis | 32.48 Bn | 30.54 Bn | 1.62 Bn |
| 4 | Takeda Pharmaceutical | 27.52 Bn | 23.46 Bn | 4.39 Bn |
| 5 | United Therapeutics | 23.16 Bn | 21.01 Bn | 648.10 Mn |
| 6 | RedHill Biopharma | 21.76 Bn | 21.76 Bn | - |
| 7 | Viatris | 20.33 Bn | 18.53 Bn | 1.16 Bn |
| 8 | Neurocrine Biosciences | 17.74 Bn | 16.43 Bn | 800.70 Mn |
| 9 | Elanco Animal Health | 12.64 Bn | 12.21 Bn | 785.00 Mn |
| 10 | Vireo Growth | 10.51 Bn | 10.36 Bn | 59.30 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 115.50 Mn |
| Dec 31, 2025 | 116.50 Mn |
| Sep 30, 2025 | 116.70 Mn |
| Jun 30, 2025 | 111.50 Mn |
| Mar 31, 2025 | 111.70 Mn |
| Dec 31, 2024 | 111.90 Mn |
| Sep 30, 2024 | 112.10 Mn |
| Jun 30, 2024 | 115.20 Mn |
| Mar 31, 2024 | 115.40 Mn |
| Dec 31, 2023 | 114.20 Mn |
| Sep 30, 2023 | 44.40 Mn |
| Jun 30, 2023 | 44.50 Mn |
| Mar 31, 2023 | 44.50 Mn |
| Dec 31, 2022 | 44.50 Mn |
| Sep 30, 2022 | 44.50 Mn |
| Jun 30, 2022 | 44.60 Mn |
| Mar 31, 2022 | 44.60 Mn |
| Dec 31, 2021 | 44.60 Mn |
| Sep 30, 2021 | 44.70 Mn |
| Jun 30, 2021 | 44.70 Mn |